Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)
Latest Information Update: 27 Nov 2024
Price :
$35 *
At a glance
- Drugs SP-0202 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi Pasteur
- 27 Nov 2024 New trial record